The Real Impact of PAD - Pluristem Therapeutics to Host Key Opinion Leader Meeting on Peripheral Artery Disease
November 29 2018 - 6:30AM
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading
regenerative medicine company developing novel placenta-based cell
therapy products, today announced that it will host a Key Opinion
Leader (KOL) meeting on Peripheral Artery Disease (PAD) on December
14, 2018 in New York City.
The meeting will feature presentations by KOLs
John Lantis, MD, Vice Chairman of the Department of Surgery and
Chief of Vascular and Endovascular Surgery at Mount Sinai West, and
Mary L. Yost, MBA, Co-Founder of The Sage Group, who will discuss
the current treatment landscape and unmet medical needs, the
economic impact, and potential market opportunities for treating
patients with PAD. Both KOLs will be available at the conclusion of
the event to answer questions.
Pluristem's management team will also provide a
corporate overview of the company's development strategy for
PLX-PAD, which is currently in a multinational pivotal Phase III
clinical study. Of note, the FDA recently approved an Expanded
Access Program (EAP) for PLX-PAD in CLI patients. It is estimated
that 5-6 million people in U.S. and Europe suffer from CLI, and
this number is projected to grow, with an estimated cost of $25
billion per year in the U.S. alone.
This event is intended for institutional
investors, sell-side analysts, investment bankers, and business
development professionals only. Please RSVP in advance if you plan
to attend, as space is limited. For those who are unable to
attend in person, a live webcast and replay will be accessible
here. If you would like to ask a question during the live Q&A,
please submit your request via email.
About Pluristem
TherapeuticsPluristem Therapeutics Inc. is a leading
regenerative medicine company developing novel placenta-based cell
therapy products. The Company has reported robust clinical trial
data in multiple indications for its patented PLX cells and is
entering late stage trials in several indications. PLX cell
products release a range of therapeutic proteins in response to
inflammation, ischemia, muscle trauma, hematological disorders, and
radiation damage. The cells are grown using the Company's
proprietary three-dimensional expansion technology and can be
administered to patients off-the-shelf, without tissue matching.
Pluristem has a strong intellectual property position;
Company-owned and operated, GMP-certified manufacturing and
research facilities; strategic relationships with major research
institutions; and a seasoned management team.
Safe Harbor StatementThis press
release contains express or implied forward-looking statements
within the Private Securities Litigation Reform Act of 1995 and
other U.S. Federal securities laws. For example, we are using
forward-looking statements when we discuss the estimated growth in
the population in the U.S. and Europe suffering from CLI and
projected cost of treatment of CLI in the U.S. These
forward-looking statements and their implications are based on the
current expectations of the management of Pluristem only, and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. The following factors, among others,
could cause actual results to differ materially from those
described in the forward-looking statements: changes in technology
and market requirements; we may encounter delays or obstacles in
launching and/or successfully completing our clinical trials; our
products may not be approved by regulatory agencies, our technology
may not be validated as we progress further and our methods may not
be accepted by the scientific community; we may be unable to retain
or attract key employees whose knowledge is essential to the
development of our products; unforeseen scientific difficulties may
develop with our process; our products may wind up being more
expensive than we anticipate; results in the laboratory may not
translate to equally good results in real clinical settings;
results of preclinical studies may not correlate with the results
of human clinical trials; our patents may not be sufficient; our
products may harm recipients; changes in legislation; inability to
timely develop and introduce new technologies, products and
applications; loss of market share and pressure on pricing
resulting from competition, which could cause the actual results or
performance of Pluristem to differ materially from those
contemplated in such forward-looking statements. Except as
otherwise required by law, Pluristem undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem,
reference is made to Pluristem's reports filed from time to time
with the Securities and Exchange Commission.
Contact:
Efrat KaduriHead of Investor and Public
Relations972-74-7108600efratk@pluristem.com
Karine Kleinhaus, MD, MPHDivisional VP, North
America1-914-512-4109karinek@pluristem.com
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Apr 2024 to May 2024
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From May 2023 to May 2024